Skip to main content

Table 4 Prevalence ratios of history of hepatitis C virus treatment by substance use pattern, rural opioid initiative cohort, 2018–2020

From: Differences in hepatitis C virus (HCV) testing and treatment by opioid, stimulant, and polysubstance use among people who use drugs in rural U.S. communities

Substance Pattern, past 30 days

Unadjusted

Adjusted

DAG-Informed Model1

PR

95% CI

aPR

95% CI

Other drug use (no opioid or stimulant use)

referent

 

referent

 

Opioid use without stimulant use

0.61

(0.22, 1.68)

0.60

(0.27, 1.32)

Stimulant use without opioid use

0.55

(0.17, 1.74)

0.55

(0.23, 1.34)

Opioid and stimulant use

0.32*

(0.11, 0.95)

0.41*

(0.19, 0.91)

  1. PR, Prevalence Ratio; aPR, adjusted Prevalence Ratio
  2. *Associated confidence interval does not include the null value (‘1’)
  3. 1. Adjusted for age and gender